Cargando…

Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits

Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ida, Mizuki, Nakamori, Shiro, Yamamoto, Shinya, Watanabe, Seimi, Imanaka‐Yoshida, Kyoko, Ishida, Masaki, Sakuma, Hajime, Yamanaka, Keiichi, Dohi, Kaoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065849/
https://www.ncbi.nlm.nih.gov/pubmed/35352879
http://dx.doi.org/10.1002/ehf2.13915
_version_ 1784699678989746176
author Ida, Mizuki
Nakamori, Shiro
Yamamoto, Shinya
Watanabe, Seimi
Imanaka‐Yoshida, Kyoko
Ishida, Masaki
Sakuma, Hajime
Yamanaka, Keiichi
Dohi, Kaoru
author_facet Ida, Mizuki
Nakamori, Shiro
Yamamoto, Shinya
Watanabe, Seimi
Imanaka‐Yoshida, Kyoko
Ishida, Masaki
Sakuma, Hajime
Yamanaka, Keiichi
Dohi, Kaoru
author_sort Ida, Mizuki
collection PubMed
description Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently high troponin after undergoing immunotherapy with ipilimumab and nivolumab, and histological evidence of amyloid deposition in the myocardium. The patient received immunosuppressive treatments based on the magnitude of troponin changes because myocarditis was clinically suspected. However, histological examination revealed the deposition of transthyretin amyloid fibrils with only minimal T‐lymphocyte infiltration and no myocyte necrosis, suggesting transthyretin cardiac amyloidosis rather than ICI myocarditis. This case highlights the importance of assessing other causes of persistently high troponin, and the necessity of incorporating comprehensive histological and immunohistochemical examinations of the endomyocardial biopsy, especially when cardiovascular magnetic resonance imaging is inconclusive.
format Online
Article
Text
id pubmed-9065849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90658492022-05-04 Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits Ida, Mizuki Nakamori, Shiro Yamamoto, Shinya Watanabe, Seimi Imanaka‐Yoshida, Kyoko Ishida, Masaki Sakuma, Hajime Yamanaka, Keiichi Dohi, Kaoru ESC Heart Fail Case Reports Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently high troponin after undergoing immunotherapy with ipilimumab and nivolumab, and histological evidence of amyloid deposition in the myocardium. The patient received immunosuppressive treatments based on the magnitude of troponin changes because myocarditis was clinically suspected. However, histological examination revealed the deposition of transthyretin amyloid fibrils with only minimal T‐lymphocyte infiltration and no myocyte necrosis, suggesting transthyretin cardiac amyloidosis rather than ICI myocarditis. This case highlights the importance of assessing other causes of persistently high troponin, and the necessity of incorporating comprehensive histological and immunohistochemical examinations of the endomyocardial biopsy, especially when cardiovascular magnetic resonance imaging is inconclusive. John Wiley and Sons Inc. 2022-03-30 /pmc/articles/PMC9065849/ /pubmed/35352879 http://dx.doi.org/10.1002/ehf2.13915 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Ida, Mizuki
Nakamori, Shiro
Yamamoto, Shinya
Watanabe, Seimi
Imanaka‐Yoshida, Kyoko
Ishida, Masaki
Sakuma, Hajime
Yamanaka, Keiichi
Dohi, Kaoru
Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title_full Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title_fullStr Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title_full_unstemmed Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title_short Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
title_sort subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065849/
https://www.ncbi.nlm.nih.gov/pubmed/35352879
http://dx.doi.org/10.1002/ehf2.13915
work_keys_str_mv AT idamizuki subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT nakamorishiro subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT yamamotoshinya subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT watanabeseimi subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT imanakayoshidakyoko subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT ishidamasaki subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT sakumahajime subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT yamanakakeiichi subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits
AT dohikaoru subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits